Disappointing sales growth of its prescription extended-release cough-and-cold product has led Vernalis to decide to close down its US commercial operations, and to seek a buyer for the whole company.
It seemed a bold strategy, when first announced in 2012, to refocus a UK biotech on selling novel prescription cough-and-cold products in the US, but Vernalis PLC's lower-than-expected sales of its lead marketed product has led to failure of the approach, and the company's board deciding to seek a buyer.
Ian Garland, the company's CEO and a strong advocate of the US-orientated commercial strategy, will step down as CEO and...
AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.
François Roger believes fixing inefficiencies is more important than playing with pricing.
Cipla’s partnered filgrastim biosimilar is expected to debut in the US in Q2 FY26 and the Indian firm expects an investment return ratio for its biosimilar engine “not too far” from that of a complex generic product amid an enabling regulatory environment.
Celltrion is set to acquire a US biologics manufacturing facility that will "eliminate" its US tariff risks and provide a ready-made production base for future expansion.
Second quarter revenue and EPS beat consensus and BMS raised its 2025 revenue guidance, but after multiple recent Phase III failures, executives said the company is reviewing studies with near-term readouts.
AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.
Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.
